Malignancies Clinical Trial
Official title:
Phase 1 Study of the Oral Platinum Agent Satraplatin in Combination With Capecitabine for the Treatment of Patients With Advanced Solid Malignancies
The purpose of this study is to determine the maximally tolerated dose (MTD) and Phase 2 recommended dose of satraplatin when administered in combination with capecitabine in patients with advanced solid malignancies.
This is a single center, open-label, non-randomized, Phase I dose finding study of the
investigational, oral cytotoxic drug, satraplatin in combination with capecitabine in
patients with advanced solid tumors for whom curative therapy is not available. Please refer
to the Eligibility Criteria below for key inclusion and exclusion criteria.
PURPOSE: The purpose of this trial is to determine a tolerable dose and schedule for the
combination of satraplatin and docetaxel when given to patients with advanced solid tumors.
WHAT IS SATRAPLATIN: Satraplatin is an oral, investigational anticancer drug that is a
member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been
clinically proven to be one of the most effective classes of anticancer therapies. Unlike
the currently marketed platinum-based drugs, satraplatin can be given orally.
;
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
| Completed |
NCT03236857 -
A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
|
Phase 1 | |
| Active, not recruiting |
NCT03005782 -
Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
|
Phase 1 | |
| Not yet recruiting |
NCT05602103 -
Acute Cardiovascular Adverse Events Occuring in Children Treated by Anticancer Drugs for Malignancies
|
||
| Completed |
NCT00316511 -
Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma
|
Phase 1 | |
| Withdrawn |
NCT05253105 -
A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT02521389 -
Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Formulations and Doses of PWT-143
|
Phase 1 | |
| Completed |
NCT01407380 -
Study of PWT33597 Mesylate in Subjects With Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT01404728 -
Longitudinal Evaluation Study of Vaginal Stenosis With and Without Pelvic Radiation Therapy
|
N/A | |
| Active, not recruiting |
NCT03678883 -
9-ING-41 in Patients With Advanced Cancers
|
Phase 2 | |
| Not yet recruiting |
NCT05929495 -
Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma
|
Phase 2 | |
| Completed |
NCT02257476 -
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT00320827 -
Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component)
|
Phase 1 |